德琪医药-B(06996)：ATG-022联合KEYTRUDA(帕博利珠单抗)±化疗的IB/II期研究于中国获授予IND批准

Core Viewpoint - The approval of the investigational new drug (IND) application for ATG-022, a CLDN18.2 antibody-drug conjugate, in combination with MSD's KEYTRUDA® and chemotherapy, marks a significant advancement in cancer treatment options [1] Group 1 - The National Medical Products Administration of China has approved the IND application for ATG-022 [1] - ATG-022 will be evaluated in a Phase Ib/II clinical trial (CLINCH-2) in combination with KEYTRUDA® and chemotherapy [1] - The collaboration with MSD (Merck & Co., Inc.) highlights the strategic partnership in developing innovative cancer therapies [1]